Completed PHASE2 INTERVENTIONAL 1-arm NCT00003369

S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer

Evaluation of Intravenously Administered Tirapazamine Plus Cisplatin in Cervical Cancer

Sponsor: National Cancer Institute (NCI)

Updated 8 times since 2017 Last updated: Jun 13, 2012 Started: Aug 31, 1998 Primary completion: Oct 31, 2003 Completion: Jul 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cervical Cancer and is currently completed. National Cancer Institute (NCI) leads this study, which shows 8 recorded versions since 1998 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — May 2023 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
SWOG Cancer Research Network

Data source: SWOG Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Ann Arbor, United States , Atlanta, United States , Billings, United States , Biloxi, United States , Boston, United States , Brooklyn, United States , Cincinnati, United States , Cleveland, United States , Columbus, United States and 47 more locations